Table II.
Clinical Relevance of Anti-PEG Antibodies
| Product | PEG conjugation | Study population | Detection of pre-existing anti-PEG | Detection of treatment induced anti-PEG | Clinical impact of pre-existing anti-PEG | Clinical impact of treatment induced anti-PEG | References |
|---|---|---|---|---|---|---|---|
| Pegloticase™ (PEG-porcine uricase) | 10-KDa PEG X9 per each of 4 protein subunits. Total of 360 methoxy PEG (mPEG) | Patients with refractory gout | Yes | Yes | Rapid clearance, loss of efficacy, increased risk of infusion reactions | Rapid clearance, loss of efficacy, increased risk of infusion reactions | (64) (63) |
| PEG-asparaginase | 5-KDa mPEG | Acute lymphoblastic leukemia patients | Yes | Yes | Inconclusive | Rapid clearance | (65) |
| PEGASYS™ (PEG-IFN-α2a) | 40-KDa single-branched bis-mPEG | HCV-infected patients | Yes | Yes | No | No | (16) |
| PEG-IFN-β1a | 20-KDa mPEG | Multiple sclerosis | Yes | Yes | Unknown | Unknown | (66) |
| Peg-IFN-γ | 20-KDa linear mPEG | HCV-infected subjects | Yes | Yes | No | No | (62) |
| PEG-intron (PEG-IFN-α2b) | 12 KDa, mPEG | HCV-infected patients | Yes | Yes | No | No | (16) |